• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

18.55 +0.05 (+0.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
January 06, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
December 23, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
 
Via Benzinga
Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug ↗
September 03, 2025
Via Stocktwits
News headline image
Earnings Scheduled For August 7, 2025 ↗
August 07, 2025
 
Via Benzinga
News headline image
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
December 08, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Updates to China’s National Reimbursement Drug List
December 07, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance
November 19, 2025
Boston, MA – November 19, 2025 – Nuvation Bio Inc. (NASDAQ: NUVB) has captured the financial spotlight, witnessing a remarkable 47.71% surge in its stock price following a stellar third-quarter 2025... 
Via MarketMinute
News headline image
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
November 06, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Participation in Investor Conferences in November and December 2025
October 31, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
October 24, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
October 15, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
October 13, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback ↗
September 11, 2025
 
Via Benzinga
Topics Earnings
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
September 10, 2025
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB
September 06, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug ↗
September 04, 2025
Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results. 
Via Benzinga
News headline image
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
September 04, 2025
 
Via Benzinga
News headline image
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
September 01, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Participation in Investor Conferences in September 2025
August 28, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
August 19, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Establishes Oncology Scientific Advisory Board
August 13, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
August 07, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
July 18, 2025
 
Via Benzinga
News headline image
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
July 10, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects ↗
June 30, 2025
Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected later. 
Via Benzinga
News headline image
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
June 30, 2025
From Zai Lab Limited
Via Business Wire
News headline image
ZAI LAB LTD-ADR (NASDAQ:ZLAB) – A High-Growth Biotech Stock Meeting Minervini’s Criteria ↗
June 16, 2025
ZAI LAB LTD-ADR (NASDAQ:ZLAB) is a high-growth biotech stock meeting Minervini’s Trend Template with strong revenue growth, technical strength, and sector leadership. 
Via Chartmill
News headline image
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
June 13, 2025
From Zai Lab Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap